Early Parkinson's Disease Monotherapy With CVN424
Early Parkinson's Disease Monotherapy With CVN424
NCT ID: NCT06006247 Phase: PHASE2 Status: COMPLETED Enrollment: 64 Completion: 2025-02-13
Conditions
Parkinson's Disease
Interventions
CVN424 150 mg, Placebo
Summary
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
Primary Outcome
Change From Baseline to Week 12 on the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III